B. Metzler seel. Sohn & Co. Holding AG Takes $1.19 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 10,409 shares of the company's stock, valued at approximately $1,189,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Riverview Trust Co bought a new position in shares of Vaxcyte in the third quarter worth $27,000. Blue Trust Inc. increased its holdings in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. Fifth Third Bancorp acquired a new position in shares of Vaxcyte in the 2nd quarter valued at approximately $35,000. J.Safra Asset Management Corp boosted its position in shares of Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after acquiring an additional 526 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its stake in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after acquiring an additional 635 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

PCVX has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Mizuho raised their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Finally, Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded up $0.15 on Friday, hitting $88.54. The stock had a trading volume of 1,614,295 shares, compared to its average volume of 1,610,634. The stock has a 50 day moving average of $107.89 and a 200 day moving average of $89.26. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Activity at Vaxcyte

In other news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 28.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 102,464 shares of company stock worth $11,455,576 over the last three months. Company insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.